Potentially predictive factors for hearing function improvement in pediatric cytomegalovirus infection therapy

Agung Triono; Elisabeth Siti Herini; Braghmandita Widya; Dian Kesumapramudya Nurputra

doi:10.14238/pi61.5.2021.235-9

Agung Triono RSUP Dr. Sardjito/FKKMK UGM
Elisabeth Siti Herini Department of Pediatrics, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Central Java
Braghmandita Widya Department of Pediatrics, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Central Java
Dian Kesumapramudya Nurputra Department of Pediatrics, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Central Java

DOI: https://doi.org/10.14238/pi61.5.2021.235-9

Keywords: CMV infection, hearing impairment, predictive factor, ganciclovir

Abstract

Background Symptomatic congenital cytomegalovirus (CMV) infection has an impact mainly on neurological sequelae, including sensorineural deafness. Because of the long-term impact, early treatment of CMV infection is mandatory. However, predictive factors for hearing function improvement in CMV infection therapy remain unexamined.

Objective To evaluate potential predictive factors for hearing improvement in pediatric CMV infection therapy.

Methods All medical record data of patients aged 0-6 years with CMV infection who completed a 6-week course of ganciclovir therapy or a combination of a 4-week course of ganciclovir and a 2-week course valganciclovir from January 2013 to December 2017 were collected. Age at onset of therapy, gender, gestational age, nutritional status, multi-organ involvement, and neurological symptoms were studied as potential predictive factors of hearing improvement in CMV therapy. The effectiveness of CMV infection therapy on improving hearing function was measured with the brainstem evoked response audiometry (BERA) test.

Results BERA tests proportion in the right, left, and best ear showed significant improvement after therapy. All variables analyzed were not statistically significant as predictive factors for hearing improvement in CMV infection therapy.

Conclusion Ganciclovir/valganciclovir therapy in CMV infection patients accounted for the improvement of hearing impairment. However, none of the assessed factors were considered predictive for improving hearing function in CMV infection therapy.

Author Biography

Braghmandita Widya, Department of Pediatrics, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Central Java

References

1. Haller TJ, Price MS, Lindsay SR, Hillas E, Seipp M, Firpo MA, Park AH. Effects of ganciclovir treatment in murine model of cytomegalovirus-induced hearing loss. The Laryngoscope. 2009; 00:1-6. DOI: 10.1002/lary.28134
2. Ross SA, Novak Z, Pati S, Boppana SB. Overview of the diagnosis of cytomegalovirus infection. Infect Disord Drug Targets. 2011;11:466-74. DOI: 10.2174/187152611797636703.
3. Fowler KB, Boppana SB. Congenital cytomegalovirus (CMV) infection and hearing deficit. J Clin Virol. 2006;35:226–31. DOI: 10.1016/j.jcv.2005.09.016.
4. Hadinegoro SRS, Moedjito U, Hapsari MMD, Alam A. Buku ajar infeksi dan pediatri tropis. Jakarta: Badan Penerbit IDAI; 2008. p. 122-7, 43-54, 276-91, 458-65.
5. Triono A, Herini ES, Indraswari BW, Nurputra DK, Wardhani S. Luaran terapi ganciclovir dan atau valganciclovir pada pasien infeksi cytomegalovirus di Instalasi Kesehatan Anak RSUP Dr Sardjito. Sari Pediatri. 2020; 22:1-6. DOI: 10.14238/sp22.1.2020.1-6.
6. Kimberlin DW, Acosta EP, Sanchez P, Sood S, Agrawa; V, Homans J, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis. 2008;197:836-45. DOI: 10.1086/528376.
7. Kim CS. Congenital and perinatal cytomegalovirus infection. Korean J Pediatr. 2010;53:14-20. DOI: 10.3345.kjp.2010.53.1.14.
8. Picone O, Simon I, Benachil A, Brunelle F, Sonigo P. Comparison between ultrasound and magnetic resonance imaging in assesment of fetal cytomegalovirus infection. Prenat Diagn. 2008;28:753-8. DOI: 10.1002/pd.2037.
9. Boppana SB, Pass RF, Britt WJ, Stagno S, Alford CA. Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis J. 1992;11:93-9. doi: 10.1097/00006454-199202000-00007.
10. Harrison GJD, Morven SE, Leonard EW, Carrie A. Uptodate. 2018. [cited YEAR MONTH DATE ]. Available from: https://www.uptodate.com/contents/congenital-cytomegalovirus-infection-clinical-features-and-diagnosis?
11. Bathia J, Shah BV, Mehta AP, Deshmukh M, Sirsat RA, Rodriguez C. Comparing serology, antigenemia assay and polymerase chain reaction for the diagnosis of cytomegalovirus infection in renal transplant patient. J Assoc Phys India. 2004;52:297-300. PMID: 15636331.
12. Kimberlin DW, Jester PM, Sanchez PJ, Ahmed A, Arav-Bogor R, Michaels MG, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015;372:933-43. DOI: 10.1056/NEJMoa1404599.
13. Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hear- ing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003;143:16-25. DOI: 10.1016/S0022-3476(03)00192-6.
14. Ohyama S, Morioka I, Fukushima S, Yamana K, Nishida K, Iwatani S, et al. Efficacy of valganciclovir treatment depends on the severity of hearing dysfunction in symptomatic infants with congenital cytomegalovirus. Int J Mol Sci. 2019;20:1388. DOI: 10.3390/ijms20061388.
15. Teissier, N.; Delezoide, A.L.; Mas, A.E.; Khung-Savatovsky, S.; Bessières, B.; Nardelli, J.; Vauloup-Fellous, C.; Picone, O.; Houhou, N.; Oury, J.F.; et al. Inner ear lesions in congenital cytomegalovirus infection of human fetuses. Acta Neuropathol. 2011;122:763-74. DOI: 10.1007/s00401-011-0895-y.
16. Acosta E, Bowlin T, Brooks J, Chiang L, Hussein I, Kimberlin D, et al. Advances in the development of therapeutic cytomegalovirus infections. The Journal Of Infectious Diseases. 2020;221(Suppl 1). DOI: 10.1093/infdis/jiz493.
17. Marsico C, Aban I, Kuo H, et al. Blood viral load in symp- tomatic congenital cytomegalovirus infection. J Infect Dis. 2019; 219:1398-1406. DOI: 10.1093/infdis/jiy695.
18. Morioka I, Kakei Y, Omori T, Nozu K, Fujioka K, Yoshikawa T, et al. Efficacy and safety of valganciclovir in patients with symptomatic congenital cytomegalovirus disease. Medicine. 2020; 99:17. DOI: 10.1097/MD.00000000000019765.
19. Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis 2017;17:e177-88. DOI: 10.1016/S1473-3099(17)30143-3.